home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

Strategies for Preparing a Successful 510(k) Premarket Notification for FDA Submission

 
  October 02, 2012  
     
 
ComplianceOnline, Online Event
2012-11-14


Why Should You Attend:

The 510(k) submission is made to the FDA to demonstrate that a subject device (to be marketed) is substantially equivalent (as least as safe and effective) to a legally marketed device (predicate device).

FDA generally requires 510(k) notification for Class II devices. The 510(k) process is relatively quick and relatively inexpensive (FDA aims for a 3 month review process). However, in reality, the review process can take considerably longer, from 6 months to one year in some cases.

This 3-hr session will focus on the FDA’s premarket notification [510(k)] submission process. The presenter will explain in detail the components and format of a 510(k) Premarket Notification and discuss strategies for preparing and submitting a successful 510(k) submission. You will also learn what questions to expect from FDA in response to a pending 510(k).

Areas Covered in the Seminar:

  • FDA regulations applicable to a 510(k) submission.
  • Overview of the 510(k) program and recent changes in the 510(k) program.
  • Identification of the 510(k) regulatory requirements.
  • Discussion of the 510(k) submission requirements for medical devices and in vitro diagnostic devices.
  • How to identify and select an appropriate Predicate Device.
  • List of applicable FDA guidance documents and reference standards.
  • Systematic methods to increase 510(k) submission quality.
  • Formatting a 510(k) for submission; 510(k) contents for medical devices and in vitro diagnostic devices; and strategies for preparing successful 510(k) notification submissions.
  • Responding a CDRH Responses to a pending 510(k).
  • Instructor’s recommendations for success.
Event Details:
 
Date:                    November 14, 2012
Time:                   10:00 AM-01:00 PM PDT
Cost:                    $399 per attendee per computer terminal
Registration:        SIgn-Up on-line now.  Add to your shopping cart.
 
 
Organized by: ComplianceOnline
Invited Speakers: Karl Nobert, is a food and drug regulatory attorney with the law firm of Squire Sanders in Washington, DC. He provides regulatory advice and counseling to both large and small domestic and international pharmaceutical companies on regulatory issues related to the U.S. Food and Drug Administration’s review and approval of new drug products. This includes counseling clients on FDA’s regulation of prescription branded and generic drugs, and over-the-counter drug products. He also has considerable experience related to the regulation of biologics including cellular and genetic therapies, and veterinary drug products. He frequently presents and has published on such topics.
 
Deadline for Abstracts: 2012-11-14
 
Registration: http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=702507?channel=hummolgen
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.